Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
Evaxion Biotech A/S (NASDAQ: EVAX) has launched an enhanced version of its AI-Immunology™ platform, featuring an updated EDEN™ AI prediction model. The new version 5.0 includes:
- A novel toxin antigen predictor
- An expanded training dataset
- Advanced protein feature prediction
These improvements are expected to accelerate vaccine development and strengthen Evaxion's position in AI-driven immunology. The platform can now deliver a new target within 24 hours, compared to years using traditional methods. The enhanced EDEN™ model's performance will be presented at the European Conference on Computational Biology in Turku, Finland.
Evaxion Biotech A/S (NASDAQ: EVAX) ha lanciato una versione migliorata della sua piattaforma AI-Immunology™, caratterizzata da un aggiornato modello di previsione EDEN™ AI. La nuova versione 5.0 include:
- Un nuovo predittore di antigeni tossici
- Un dataset di addestramento ampliato
- Previsioni avanzate delle caratteristiche proteiche
Questi miglioramenti si prevede che accelereranno lo sviluppo dei vaccini e rafforzeranno la posizione di Evaxion nell'immunologia basata sull'IA. La piattaforma è ora in grado di fornire un nuovo obiettivo entro 24 ore, rispetto a anni utilizzando metodi tradizionali. Le prestazioni del modello EDEN™ migliorato saranno presentate alla Conferenza Europea sulla Biologia Computazionale a Turku, Finlandia.
Evaxion Biotech A/S (NASDAQ: EVAX) ha lanzado una versión mejorada de su plataforma AI-Immunology™, que incluye un modelo de predicción EDEN™ AI actualizado. La nueva versión 5.0 incluye:
- Un nuevo predictor de antígenos tóxicos
- Un conjunto de datos de entrenamiento ampliado
- Predicciones avanzadas de características de proteínas
Se espera que estas mejoras aceleren el desarrollo de vacunas y fortalezcan la posición de Evaxion en inmunología impulsada por IA. La plataforma ahora puede proporcionar un nuevo objetivo en 24 horas, en comparación con años utilizando métodos tradicionales. El rendimiento del modelo EDEN™ mejorado se presentará en la Conferencia Europea de Biología Computacional en Turku, Finlandia.
Evaxion Biotech A/S (NASDAQ: EVAX)는 업데이트된 EDEN™ AI 예측 모델이 포함된 AI-Immunology™ 플랫폼의 향상된 버전을 출시했습니다. 새로운 버전 5.0에는 다음이 포함됩니다:
- 새로운 독소 항원 예측기
- 확대된 훈련 데이터셋
- 고급 단백질 특징 예측
이러한 개선 사항은 백신 개발을 가속화할 것으로 예상되며 Evaxion의 AI 기반 면역학에서의 입지를 강화할 것입니다. 이제 플랫폼은 전통적인 방법에 비해 24시간 이내에 새로운 목표를 제시할 수 있습니다. 향상된 EDEN™ 모델의 성능은 핀란드 투르쿠에서 열리는 유럽 컴퓨터 생물학 회의에서 발표될 예정입니다.
Evaxion Biotech A/S (NASDAQ: EVAX) a lancé une version améliorée de sa plateforme AI-Immunology™, comprenant un modèle de prédiction EDEN™ AI mis à jour. La nouvelle version 5.0 comprend :
- Un nouveau prédicteur d'antigène toxique
- Un ensemble de données d'entraînement élargi
- Des prédictions avancées des caractéristiques des protéines
Ces améliorations devraient accélérer le développement des vaccins et renforcer la position d'Evaxion dans le domaine de l'immunologie basée sur l'IA. La plateforme peut désormais fournir un nouvel objectif en 24 heures, contre des années avec les méthodes traditionnelles. Les performances du modèle EDEN™ amélioré seront présentées lors de la Conférence européenne sur la biologie computationnelle à Turku, en Finlande.
Evaxion Biotech A/S (NASDAQ: EVAX) hat eine verbesserte Version seiner AI-Immunologie™-Plattform gestartet, die ein aktualisiertes EDEN™ AI-Vorhersagemodell umfasst. Die neue Version 5.0 enthält:
- Ein neuartiger Toxin-Antigen-Vorhersager
- Ein erweitertes Trainingsdatenset
- Erweiterte Vorhersagen von Proteinmerkmalen
Diese Verbesserungen werden voraussichtlich die Impfstoffentwicklung beschleunigen und die Position von Evaxion im AI-gesteuerten Immunologiebereich stärken. Die Plattform kann nun innerhalb von 24 Stunden ein neues Ziel bereitstellen, im Vergleich zu Jahren, die mit traditionellen Methoden benötigt werden. Die Leistung des verbesserten EDEN™-Modells wird auf der Europäischen Konferenz für Computerbiologie in Turku, Finnland, vorgestellt.
- Launch of improved AI-Immunology™ platform with enhanced EDEN™ AI prediction model
- New toxin antigen predictor allows for development of improved bacterial vaccines
- Ability to deliver one new target within 24 hours, significantly faster than traditional methods
- Expanded training dataset and advanced protein feature prediction capabilities
- Clinically validated platform with prediction scores correlating to pre-clinical and clinical readouts
- None.
Insights
The launch of Evaxion's improved AI-Immunology™ platform represents a significant leap in vaccine development technology. The enhanced EDEN™ AI prediction model, now capable of predicting toxin antigens, could revolutionize bacterial vaccine creation. This advancement is particularly noteworthy as it addresses a critical aspect of vaccine efficacy - neutralizing bacterial toxins that contribute to diseases.
The platform's ability to deliver new targets within 24 hours, compared to years using traditional methods, is a game-changer in the fast-paced world of vaccine development. The expanded dataset and advanced protein feature prediction using protein language models suggest a more robust and accurate system. However, it's important to note that while AI predictions are promising, they still require rigorous clinical validation.
The correlation between the AI's prediction scores and pre-clinical/clinical readouts is encouraging, but investors should remain cautious until more real-world results are available. This development positions Evaxion as a frontrunner in AI-driven vaccine discovery, potentially attracting partnerships and investment in the burgeoning TechBio sector.
Evaxion's upgraded AI-Immunology™ platform marks a significant advancement in the vaccine development landscape. The inclusion of a toxin antigen predictor in EDEN™ 5.0 addresses a important gap in bacterial vaccine design. This feature could potentially accelerate the development of more effective vaccines against pathogens where toxins play a key role in virulence.
The platform's agnostic approach to delivery modalities offers flexibility in vaccine design, which could be particularly valuable as new vaccine technologies emerge. The streamlined process for curating training data using large language models, coupled with expert curation, suggests a scalable approach to keeping the AI model updated with the latest scientific knowledge.
However, investors should note that while AI-driven approaches can significantly speed up target identification, the path from target discovery to a marketable vaccine remains long and complex. The true value of this technology will be realized when Evaxion can demonstrate successful progression of AI-discovered targets through clinical trials.
- The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature
- The launch will expectedly improve Evaxion’s ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology™ from potential partners
- New data demonstrating the improved performance of EDEN™ will be presented today at the European Conference on Computational Biology in Turku, Finland
COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™ AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.
Bacterial toxins are often key contributors to disease, making their neutralization essential for developing effective vaccines. The upgraded EDEN™ model improves the prediction of bacterial toxins for vaccine development. With greater speed and accuracy, it enables Evaxion to rapidly identify the critical toxin targets to include in vaccines.
“Today’s launch of the improved EDEN™ AI prediction model marks an important milestone for Evaxion, further strengthening our AI-Immunology™ platform. As one of the few truly AI-first TechBio companies, our AI-Immunology™ platform is at the forefront of innovation. We will continue to invest in its development and refinement to further improve our ability to discover novel targets and develop advanced vaccines,” says Christian Kanstrup, CEO of Evaxion.
The AI-Immunology™ platform uses advanced AI and machine learning technologies to design and develop novel vaccine candidates addressing significant unmet needs. Its AI prediction models are applied in cancer and infectious diseases and scalable to other therapeutic areas. The platform can deliver one new target within just 24 hours compared to years by using traditional methods and is delivery modality agnostic. The predictive capabilities of the AI-Immunology™ platform are robustly validated as the target’s prediction score has been shown to correlate with pre-clinical and clinical readouts.
The EDEN™ prediction model is one of five models constituting the AI-Immunology™ platform. It is used to identify B-cell antigens included in infectious disease vaccines. The new version 5.0 features the following updates:
- Novel bacterial toxin antigen predictor: We have trained new machine learning models, improving the accuracy and reliability of toxin antigen prediction
- Expanded training dataset: We have streamlined the process for curating additional training data from published sources using retrieval-augmented generation with large language models, followed by manual domain expert curation
- Advanced protein feature prediction: We developed a new building block for protein feature prediction using protein language models, enhancing the model's architecture and capability to predict various protein characteristics
The data documenting the features and performance of the new EDEN™ prediction model will be presented today in a poster session at the European Conference on Computational Biology (ECCB) in Turku, Finland.
ECCB presentation details:
| Poster title: | Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens |
| Poster#: | 172 |
| Track: | Poster session 1 |
| Location: | Logomo, Junakatu 9, Turku, Finland |
| Date/Time: | September 19, 2024, at 17.00-18.30CEST |
| Presenter: | Christian Garde |
Link to abstract on the ECCB website.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of proprietary AI models PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity of the patient’s immune system. AI-Immunology™ advanced computational modeling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic and personalized approach to combat fast-evolving pathogens and malignant cells.
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
Source: Evaxion Biotech
FAQ
What new features does Evaxion's EDEN™ 5.0 AI model include?
How quickly can Evaxion's AI-Immunology™ platform deliver a new target?
Where will Evaxion (EVAX) present data on the new EDEN™ prediction model?
What is the main advantage of Evaxion's new toxin antigen predictor for EVAX stock?
